Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q52685657 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241221010718.0 | ||
| 008 | 241221nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q52685657 | ||
| 024 | ‡a 0000-0002-4486-5757 ‡2 orcid | ||
| 024 | ‡a 36662471600 ‡2 scopus | ||
| 035 | ‡a (OCoLC)Q52685657 | ||
| 100 | 0 | ‡a রেচেল ই মিলার ‡9 bn | |
| 375 | ‡a 2 ‡2 iso5218 | ||
| 400 | 0 | ‡a Rachel E. Miller ‡c researcher ‡9 en | |
| 400 | 0 | ‡a Rachel E Miller ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. | ||
| 670 | ‡a Author's An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis | ||
| 670 | ‡a Author's Can we target CCR2 to treat osteoarthritis? The trick is in the timing! | ||
| 670 | ‡a Author's CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy | ||
| 670 | ‡a Author's Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis | ||
| 670 | ‡a Author's Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. | ||
| 670 | ‡a Author's Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain | ||
| 670 | ‡a Author's Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. | ||
| 670 | ‡a Author's Effects of the combination of microfracture and self-assembling Peptide filling on the repair of a clinically relevant trochlear defect in an equine model | ||
| 670 | ‡a Author's Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets | ||
| 670 | ‡a Author's Growth Factor Delivery Through Self-assembling Peptide Scaffolds | ||
| 670 | ‡a Author's Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? | ||
| 670 | ‡a Author's PCSK6-mediated corin activation is essential for normal blood pressure | ||
| 670 | ‡a Author's Peripheral Mechanisms Contributing to Osteoarthritis Pain. | ||
| 670 | ‡a Author's The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain | ||
| 670 | ‡a Author's Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. | ||
| 670 | ‡a Author's Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification | ||
| 670 | ‡a Author's TRPC5 Does Not Cause or Aggravate Glomerular Disease | ||
| 670 | ‡a Author's What is new in pain modification in osteoarthritis? | ||
| 909 | ‡a (orcid) 0000000244865757 ‡9 1 | ||
| 909 | ‡a (scopus) 36662471600 ‡9 1 | ||
| 919 | ‡a aggrecanfragmentdrivesosteoarthritispainthroughtolllikereceptor2 ‡A An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. ‡9 1 | ||
| 919 | ‡a emergingrolefortolllikereceptorsattheneuroimmuneinterfaceinosteoarthritis ‡A An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis ‡9 1 | ||
| 919 | ‡a canwetargetccr2totreatosteoarthritisthetrickisinthetiming ‡A Can we target CCR2 to treat osteoarthritis? The trick is in the timing! ‡9 1 | ||
| 919 | ‡a ccl2andccr2regulatepainrelatedbehaviourandearlygeneexpressioninposttraumaticmurineosteoarthritisbutcontributelittletochondropathy ‡A CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy ‡9 1 | ||
| 919 | ‡a chemogeneticinhibitionofpainneuronsinamousemodelofosteoarthritis ‡A Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis ‡9 1 | ||
| 919 | ‡a chemokinereceptor7ccr7deficiencyleadstodelayeddevelopmentofjointdamageandfunctionaldeficitsinamurinemodelofosteoarthritis ‡A Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. ‡9 1 | ||
| 919 | ‡a currentstatusofnervegrowthfactorantibodiesforthetreatmentofosteoarthritispain ‡A Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain ‡9 1 | ||
| 919 | ‡a deliveringheparinbindinginsulinlikegrowthfactor1withselfassemblingpeptidehydrogels ‡A Delivering heparin-binding insulin-like growth factor 1 with self-assembling peptide hydrogels. ‡9 1 | ||
| 919 | ‡a effectsofthecombinationofmicrofractureandselfassemblingpeptidefillingontherepairofaclinicallyrelevanttrochleardefectinanequinemodel ‡A Effects of the combination of microfracture and self-assembling Peptide filling on the repair of a clinically relevant trochlear defect in an equine model ‡9 1 | ||
| 919 | ‡a geneticallyengineeredmousemodelsrevealtheimportanceofproteasesasosteoarthritisdrugtargets ‡A Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets ‡9 1 | ||
| 919 | ‡a growthfactordeliverythroughselfassemblingpeptidescaffolds ‡A Growth Factor Delivery Through Self-assembling Peptide Scaffolds ‡9 1 | ||
| 919 | ‡a nervegrowthfactorblockadeforthemanagementofosteoarthritispainwhatcanwelearnfromclinicaltrialsandpreclinicalmodels ‡A Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? ‡9 1 | ||
| 919 | ‡a pcsk6mediatedcorinactivationisessentialfornormalbloodpressure ‡A PCSK6-mediated corin activation is essential for normal blood pressure ‡9 1 | ||
| 919 | ‡a roleofperipheralnociceptiveneuronsinthepathophysiologyofosteoarthritispain ‡A The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain ‡9 1 | ||
| 919 | ‡a therapeuticeffectsofanantiadamts5antibodyonjointdamageandmechanicalallodyniainamurinemodelofosteoarthritis ‡A Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. ‡9 1 | ||
| 919 | ‡a translationaldevelopmentofanadamts5antibodyforosteoarthritisdiseasemodification ‡A Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification ‡9 1 | ||
| 919 | ‡a trpc5doesnotcauseoraggravateglomerulardisease ‡A TRPC5 Does Not Cause or Aggravate Glomerular Disease ‡9 1 | ||
| 919 | ‡a whatisnewinpainmodificationinosteoarthritis ‡A What is new in pain modification in osteoarthritis? ‡9 1 | ||
| 919 | ‡a peripheralmechanismscontributingtoosteoarthritispain ‡A Peripheral Mechanisms Contributing to Osteoarthritis Pain. ‡9 1 | ||
| 946 | ‡a a ‡9 1 | ||
| 996 | ‡2 ISNI|0000000050634272 | ||
| 996 | ‡2 J9U|987007336524605171 | ||
| 996 | ‡2 BNF|15051825 | ||
| 996 | ‡2 J9U|987009156776905171 | ||
| 996 | ‡2 DNB|118956388 | ||
| 996 | ‡2 LC|n 99834899 | ||
| 996 | ‡2 LC|n 82050003 | ||
| 996 | ‡2 LC|no2014153100 | ||
| 996 | ‡2 LC|no2022067736 | ||
| 996 | ‡2 ISNI|000000003122346X | ||
| 996 | ‡2 ISNI|0000000139227315 | ||
| 996 | ‡2 LC|n 2022035293 | ||
| 996 | ‡2 LC|no2001082885 | ||
| 996 | ‡2 LC|n 82015882 | ||
| 996 | ‡2 LC|no2013113181 | ||
| 996 | ‡2 LC|n 2001003616 | ||
| 996 | ‡2 DE633|pe30112960 | ||
| 996 | ‡2 LC|n 87106644 | ||
| 996 | ‡2 J9U|987007364493005171 | ||
| 996 | ‡2 ISNI|0000000037799208 | ||
| 996 | ‡2 CAOONL|ncf10081345 | ||
| 996 | ‡2 LC|no2009175859 | ||
| 996 | ‡2 LC|no2014076612 | ||
| 996 | ‡2 SUDOC|20172717X | ||
| 996 | ‡2 RERO|A012411778 | ||
| 996 | ‡2 ISNI|0000000463422382 | ||
| 996 | ‡2 BIBSYS|90719768 | ||
| 996 | ‡2 ISNI|0000000443594291 | ||
| 996 | ‡2 ISNI|0000000496586922 | ||
| 996 | ‡2 BIBSYS|90522716 | ||
| 996 | ‡2 RERO|A027482090 | ||
| 996 | ‡2 LC|no 98032941 | ||
| 996 | ‡2 SUDOC|203513649 | ||
| 996 | ‡2 NLA|000049865062 | ||
| 996 | ‡2 ISNI|0000000384028176 | ||
| 996 | ‡2 W2Z|1512719457324 | ||
| 996 | ‡2 ISNI|0000000021611960 | ||
| 996 | ‡2 SUDOC|22338366X | ||
| 996 | ‡2 BIBSYS|6014871 | ||
| 996 | ‡2 LC|n 2024031732 | ||
| 996 | ‡2 LC|n 94067176 | ||
| 996 | ‡2 LC|n 2017027251 | ||
| 996 | ‡2 RERO|A003595699 | ||
| 996 | ‡2 NII|DA01841418 | ||
| 996 | ‡2 RERO|A014078885 | ||
| 996 | ‡2 CAOONL|ncf10974058 | ||
| 996 | ‡2 ISNI|0000000021970920 | ||
| 996 | ‡2 ISNI|0000000462552564 | ||
| 996 | ‡2 BNF|17713983 | ||
| 996 | ‡2 LC|no2008016472 | ||
| 996 | ‡2 BIBSYS|2132383 | ||
| 996 | ‡2 BNF|13968914 | ||
| 996 | ‡2 ISNI|0000000446206573 | ||
| 996 | ‡2 LC|n 85293809 | ||
| 996 | ‡2 ISNI|0000000035381852 | ||
| 996 | ‡2 LC|no 98057638 | ||
| 996 | ‡2 NTA|412714124 | ||
| 996 | ‡2 CAOONL|ncf10131769 | ||
| 996 | ‡2 LC|n 82154259 | ||
| 996 | ‡2 LC|n 87829335 | ||
| 996 | ‡2 ISNI|0000000120765383 | ||
| 996 | ‡2 LC|no 94009381 | ||
| 996 | ‡2 LC|no2016083156 | ||
| 996 | ‡2 LC|n 77007010 | ||
| 996 | ‡2 LC|no2014143945 | ||
| 996 | ‡2 LC|nr 93025247 | ||
| 996 | ‡2 NTA|070302014 | ||
| 996 | ‡2 LC|n 2023031586 | ||
| 996 | ‡2 J9U|987007360579605171 | ||
| 996 | ‡2 CAOONL|ncf10253498 | ||
| 996 | ‡2 J9U|987007425177405171 | ||
| 996 | ‡2 NKC|ntk20211127083 | ||
| 996 | ‡2 LC|n 88667023 | ||
| 996 | ‡2 LC|n 2011056539 | ||
| 996 | ‡2 LIH|LNB:C_i__h__x_;=CW | ||
| 996 | ‡2 DNB|1237008735 | ||
| 996 | ‡2 SUDOC|15203160X | ||
| 996 | ‡2 LC|nb2017011328 | ||
| 996 | ‡2 ISNI|0000000035391006 | ||
| 996 | ‡2 RERO|A026738689 | ||
| 996 | ‡2 LC|no2020088053 | ||
| 996 | ‡2 NTA|121942538 | ||
| 996 | ‡2 LC|no2011089963 | ||
| 996 | ‡2 VLACC|000046196 | ||
| 996 | ‡2 J9U|987007323786205171 | ||
| 996 | ‡2 ISNI|0000000045492943 | ||
| 996 | ‡2 RERO|A016562131 | ||
| 996 | ‡2 DNB|1122699778 | ||
| 996 | ‡2 LC|n 2001016341 | ||
| 996 | ‡2 ISNI|0000000078936686 | ||
| 996 | ‡2 LC|no2024118959 | ||
| 996 | ‡2 ISNI|000000039549376X | ||
| 996 | ‡2 RERO|A012337645 | ||
| 996 | ‡2 J9U|987007346670805171 | ||
| 996 | ‡2 BIBSYS|14016990 | ||
| 996 | ‡2 J9U|987007379422405171 | ||
| 996 | ‡2 LC|n 95092935 | ||
| 996 | ‡2 N6I|vtls000050152 | ||
| 996 | ‡2 ISNI|0000000030768951 | ||
| 996 | ‡2 CAOONL|ncf10669928 | ||
| 996 | ‡2 ISNI|0000000034017477 | ||
| 996 | ‡2 DNB|1351238345 | ||
| 996 | ‡2 LC|no2010066737 | ||
| 996 | ‡2 DBC|87097991576090 | ||
| 996 | ‡2 CAOONL|ncf11588288 | ||
| 996 | ‡2 LC|n 2019007441 | ||
| 996 | ‡2 BIBSYS|10079984 | ||
| 996 | ‡2 CAOONL|ncf12122342 | ||
| 996 | ‡2 ISNI|0000000082937534 | ||
| 996 | ‡2 LC|no2009098653 | ||
| 996 | ‡2 LC|no2012142760 | ||
| 996 | ‡2 LC|n 96055951 | ||
| 996 | ‡2 LC|n 81021404 | ||
| 996 | ‡2 J9U|987007369623905171 | ||
| 996 | ‡2 RERO|A009997568 | ||
| 996 | ‡2 BIBSYS|99049304 | ||
| 996 | ‡2 BIBSYS|90142845 | ||
| 996 | ‡2 BIBSYS|62999 | ||
| 996 | ‡2 LC|no2015140794 | ||
| 996 | ‡2 SUDOC|188596402 | ||
| 996 | ‡2 LC|nr 89004296 | ||
| 996 | ‡2 BIBSYS|1512719457324 | ||
| 996 | ‡2 LC|no2015019857 | ||
| 996 | ‡2 LC|no 96006431 | ||
| 996 | ‡2 DNB|1331085454 | ||
| 996 | ‡2 ISNI|0000000083427413 | ||
| 996 | ‡2 BLBNB|001504669 | ||
| 996 | ‡2 BIBSYS|90209350 | ||
| 996 | ‡2 LC|n 87125257 | ||
| 996 | ‡2 BIBSYS|90698358 | ||
| 996 | ‡2 J9U|987007366757805171 | ||
| 996 | ‡2 LC|no2015024081 | ||
| 996 | ‡2 BNE|XX4740919 | ||
| 996 | ‡2 LC|no2011120243 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
